A team of researchers led by University of California, Riverside biomedical scientists has identified a small, previously ...

Microangiopathy is a disorder of small blood vessels. Diabetic microangiopathy, or retinopathy, is a predominant abnormality of retinal vasculature and is the leading cause of blindness among ...

Scotland’s high-growth businesses shared £1.5 million as the latest recipients of support through the Scottish Edge pitching ...

The program is designed with a novel, liver-detargeting, muscle-tropic capsid intended to improve safety and ...

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike to ...

IQ Consortium experts explain how advanced chromatographic and analytical strategies are improving the bioanalysis, metabolite characterization, and regulatory readiness of RNA-based therapeutics.

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of ...

While Imvax’s autologous immunotherapy IGV-001 missed the primary endpoint of progression-free survival in a Phase IIb trial, ...

The data demonstrated that finite-duration 24-week AHB-137 monotherapy achieved a 30% functional cure rate at Week 72 (EOF) in patients with baseline HBsAg 100--1,000 IU/mL. This finding strengthens ...

Discover Stoke Therapeutics' promising RNA therapies and market outlook. Learn the risks and commercial potential before investing in STOK shares.